Kush Parmar sold $1.1M of TRDA
director at Entrada Therapeutics, Inc.. 155,255 shares at an average of $6.95, traded Aug 6, 2026, filed Aug 10, 2026.
Score components
- +15RoleDirector
- +25Trade size$1.1M at market
- 0Share of holdings soldSold 5.5% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001664281-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 6, 2026 | SOpen-market sale Common Stockindirect: By 5AM Ventures V, L.P. | -10,494 | $7.00 | $73k | 2,836,098 | Aug 10, 2026 |
| Aug 7, 2026 | SOpen-market sale Common Stockindirect: By 5AM Ventures V, L.P. | -52,317 | $6.85 | $358k | 2,783,781 | Aug 10, 2026 |
| Aug 10, 2026 | SOpen-market sale Common Stockindirect: By 5AM Ventures V, L.P. | -92,444 | $7.00 | $647k | 2,691,337 | Aug 10, 2026 |
Related signals
Other insiders at Entrada Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | Entrada Therapeutics, Inc. | MPM BioVentures 2014, L.P. owner | $1.9M 259,837 shares | -6% | |
| 45Moderate | Entrada Therapeutics, Inc. | Mpm Bioventures 2018, L.p. owner | $1.9M 259,837 shares | -6% | |
| 40Moderate | Entrada Therapeutics, Inc. | MPM BioVentures 2014, L.P. owner | $617k 86,482 shares | -2% | |
| 40Moderate | Entrada Therapeutics, Inc. | Mpm Bioventures 2018, L.p. owner | $617k 86,482 shares | -2% | |
| 40Moderate | Entrada Therapeutics, Inc. | MPM BioVentures 2014, L.P. owner | $616k 86,914 shares | -2% | |
| 40Moderate | Entrada Therapeutics, Inc. | Mpm Bioventures 2018, L.p. owner | $616k 86,914 shares | -2% | |
| 37Weak | Entrada Therapeutics, Inc. | MPM BioVentures 2014, L.P. owner | $462k 62,714 shares | -1% | |
| 37Weak | Entrada Therapeutics, Inc. | Mpm Bioventures 2018, L.p. owner | $462k 62,714 shares | -1% | |
| 37Weak | Entrada Therapeutics, Inc. | 5AM Ventures V, L.P. owner | $432k 62,811 shares | -2% | |
| 42Moderate | Entrada Therapeutics, Inc. | 5AM Ventures V, L.P. owner | $807k 116,474 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.